Mesenchymal Stem Cells Market Size, Share, By Treatment Type (Autologous, Allogeneic), By Product (Cell Sourcing, Culture & Cryopreservation, Others), By Source of Isolation (Bone Marrow, Cord Blood, Peripheral Blood, Lungs, Others) By Application (Disease modelling, Drug development and discovery, Stem cell banking, Tissue engineering, Toxicology studies and Geography) and By Region – Market Trends, Analysis and Forecast till 2034

Report Code: PMI494222 | Publish Date: May 2024 | No. of Pages: 180

Mesenchymal Stem Cells Market Companies

  • Axol Biosciences Ltd.
  • Brainstorm Cell Therapeutics Inc.
  • Cell Applications Inc.
  • Celprogen Inc.
  • Cyagen Biosciences Inc.
  • Genlantis Inc.
  • Lonza Group AG
  • Merck KGaA
  • Pluristem Therapeutics Inc.

Recent News:

  • In November 2023, the US FDA granted a clearance to BrainStorm Cell Limited to discuss the future regulatory pathway for NurOwn in the treatment of the neurodegenerative disease, amyotrophic lateral sclerosis (ALS). NurOwn is a promising experimental therapeutic approach that uses MSCs for therapeutic purposes.
  • In June 2022, the University of Technology Sydney developed a 3D printing system to harvest stem cells from a bioreactor. Stem cells treat many diseases and injuries, including diabetes, arthritis, cancer, and more.
  • In September 2021, Cynata Therapeutics Limited announced a strategic partnership with Fujifilm Corporation. As part of this partnership, Fujifilm provides clinical and commercial manufacturing services as well as supplies Cyanta's MSC therapy products.
  • In June 2021, Essent Biologics launched human MSCs (hMSCs) for research in regenerative medicine, biopharmaceuticals and cell therapy. These hMSCs are highly specific and have a low migration rate, with each vial containing more than one million cells after thawing and have a low number of migrating cells, reflecting the growing potential of MSCs in regenerative medicine. create and research biopharmaceuticals.
  • In April 2020, the Canadian Stem Cell Network (SCN) funded a $300,000 project to evaluate optimal MSC dosing to design effective treatments to reduce the impact of respiratory disorders associated with SARS-CoV-2 infection.